Flags dropped and bureaucrats talked as the European Medicines Agency prepared its move to Amsterdam from London ahead of Brexit, a pharmaceutical industry publication reported.
“The European Medicines Agency monitors the quality and safety of medicines for both humans and animals. In addition, it assesses new and innovative medicines as efficiently as possible for safety, efficacy and quality, so that they can enter the European market with the least possible delay, and EMA remains ready to act quickly if there are problems with a medicine,” according to the Invest In Holland website.
The move will attract 36,000 visitors annually to The Netherlands, Invest in Holland said.
Major multinationals and innovative biotech companies such as Janssen, Merck (MSD), Amgen, Sanofi, Genmab, Synthon, AstraZeneca, Kite Pharma, Aduro Biotech, Galapagos, AbbVie, Kiadis, Pharming, Merus and PRA Health Sciences, already make Holland one of the most innovative countries in the world for BioPharmaceuticals.
For more information on the Dutch bioscience sector, click here.